Landmark Alzheimer’s drug approval confounds research community

Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease.

Bibliographic Details

Published in:	Nature (London) 2021-06, Vol.594 (7863), p.309-310
Main Author:	Mullard, Asher
Format:	Article
Language:	eng
Subjects:	Alzheimer's disease Antibodies Biological products industry Brain research Clinical trials Cognition & reasoning Cognitive ability Datasets Drug dosages Drug therapy FDA approval Hypotheses Medical research Neurodegenerative diseases Patients Product development Regulatory approval Researchers
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!